Samantha Shenoy, NP, MSN, provides nursing guidance on teclistamab/subcutaneous daratumumab’s second-line approval in multiple myeloma. On March 5, the FDA approved the combination of teclistamab ...

Having dealt with difficult-to-diagnose breast cancer herself, Patricia Jakel, MN, RN, AOCN, is all too familiar with the need for vigilant monitoring, even when that goes beyond what is recommended.

What should oncology nurses and advanced practice providers understand about GLP-1 RAs in the care of patients with breast ...

Data show that sentinel lymph node biopsy is becoming less routine for older women with breast early stage HR-positive, HER2-negative breast cancer.

Antonio Ocejo, MD, discusses supportive care implications from new data comparing ipilimumab/nivolumab in older vs younger ...

A real-world study found rates of toxicity-related T-DXd discontinuation in HER2-low metastatic breast cancer similar to those observed in DESTINY-Breast04. A real-world cohort of patients with ...

While the combination of pembrolizumab with standard-of-care (SOC) radiation, and androgen deprivation therapy with or without olaparib (Lynparza) was found generally feasible in high-risk localized ...

While every patient with cancer will have psychosocial needs, understanding when to assess those needs and what professionals to connect a patient with are key to supporting patie ...

Zongertinib has been granted accelerated approval in NSCLC harboring HER2 TKD mutations as part of the Commissioner’s ...

A significant portion of patients with locally advanced breast cancer receiving ultra-hypofractionation radiotherapy responded to treatment. Ultra-hypofractionated radiotherapy showed signs of ...

Antonio Ocejo, MD, discusses supportive care implications from new data comparing ipilimumab/nivolumab in older vs younger age groups with mccRCC.